NAPLES, Fla., July 20, 2018 /PRNewswire-PRWeb/ --áDr. Joseph V. Pergolizzi, Jr., CEO of
"I have enjoyed serving on the Johns Hopkins faculty for many years; however, I have decided that it's time for me to focus on nonacademic opportunities that can have a major impact on existing unmet medical needs such as atrial fibrillation [AF]," said Pergolizzi.
"AF is a common type of arrhythmia estimated to be responsible for 15-20 percent of all strokes," Pergolizzi added. "Progress is accelerating on Native Cardio's Targeted Tissue Delivery System«, initially aimed at reducing postoperative atrial fibrillation [POAF], which can affect up to 60 percent of patients following surgery."
Native Cardio's Targeted Tissue Delivery System« is a novel, multimodal treatment for postoperative and chronic AF and is designed to be an on-demand therapy that aligns with existing clinical procedures and care pathways.
Dr. Pergolizzi has led the clinical investigation and strategic commercialization of a number of disruptive pharmaceutical and medical device products and has more than 20 years of experience with medical device and pharmaceutical product development. He also serves as COO of NEMA Research, Inc. of Naples, Fla. and executive chairman of Neumentum, Inc. of Palo Alto, Calif. _____________
About Native Cardio:
Native Cardio, Inc. of Naples, Fla. is a medical device and pharmaceutical development company committed to restoring quality of life to patients. It embraces the ever-changing healthcare environment by identifying current and future unmet needs in cardiovascular health, and creates innovative medical products to address them. Native Cardio utilizes the latest technology to develop products that use a minimally invasive medical pathway to treat patients while prioritizing cost efficiency for both the patient and the healthcare delivery system. For more information, please visit http://www.nativecvs.com.
SOURCE Native Cardio, Inc.
Subscribe to our Free Newsletters!